Tuesday, April 28, 2026 6:07:52 PM
I am adding a “check figure” to the discussion regarding the potential Total Short Position on NWBO.
The Data:
- Votes cast at 12/29/25 ASM meeting: 1.192B (This is a 76% voting participation rate, suspiciously high for a 97% retail ownership)
https://www.stocktitan.net/sec-filings/NWBO/8-k-northwest-biotherapeutics-inc-reports-material-event-7422d8925fa2.html
- Retail owns ~97.7%
- Insiders/institutions own ~2.3% (assume voting rate 100%)
- NWBO outstanding shares @ 12/31/25 = 1.567B
- National average Retail Voting Rate: 28% (Broadridge ProxyPulse Report, page 7)
https://www.broadridge.com/_assets/pdf/2025proxypulse-updated.pdf
The Math (Implied Total Short Position):
Step 1: Retail votes at ASM = 1.165B (97.7% X 1.19B)
Step 2: Calculate the implied Retail shares voted, based on various voting participation rates:
- At 25%: 4.66B
- At 28% (national average): 4.16B
- At 40%: 2.91B
- At 50%: 2.33B
Step 3: Calculate Implied Naked Short Position (Implied shares less 1.567B official OS)
- At 25%: 3.12B
- At 28%: 2.62B
- At 40%: 1.37B
- At 50%: 0.79B
Summary
This is just a check figure, but the math suggests a potential 2.62B shares, short position.
I would not be surprised if the EZPZ Trading website, which currently states a 1.5B total short position (1.44B synthetic), turns out to be substantially correct, or even too conservative.
https://ezpztrading.com/market-data/stocks/short-interest/?symbol=NWBO
Each person can plug in their own assumptions, but the “over-voting” is a massive statistical anomaly that we as Retail NWBO investors cannot ignore.
Side notes:
1. Is 28% too conservative? The Broadridge report say small/microcap companies have the lowest participation rates. So a more realistic OTC average rate could imply an even larger total short position.
2. “Trimming services”: Even if 3B or 4B shares were “eligible” to vote, NWBO would never see it. Brokerages use 'Trimming Services' to remove over-voting before results are certified.
The Data:
- Votes cast at 12/29/25 ASM meeting: 1.192B (This is a 76% voting participation rate, suspiciously high for a 97% retail ownership)
https://www.stocktitan.net/sec-filings/NWBO/8-k-northwest-biotherapeutics-inc-reports-material-event-7422d8925fa2.html
- Retail owns ~97.7%
- Insiders/institutions own ~2.3% (assume voting rate 100%)
- NWBO outstanding shares @ 12/31/25 = 1.567B
- National average Retail Voting Rate: 28% (Broadridge ProxyPulse Report, page 7)
https://www.broadridge.com/_assets/pdf/2025proxypulse-updated.pdf
The Math (Implied Total Short Position):
Step 1: Retail votes at ASM = 1.165B (97.7% X 1.19B)
Step 2: Calculate the implied Retail shares voted, based on various voting participation rates:
- At 25%: 4.66B
- At 28% (national average): 4.16B
- At 40%: 2.91B
- At 50%: 2.33B
Step 3: Calculate Implied Naked Short Position (Implied shares less 1.567B official OS)
- At 25%: 3.12B
- At 28%: 2.62B
- At 40%: 1.37B
- At 50%: 0.79B
Summary
This is just a check figure, but the math suggests a potential 2.62B shares, short position.
I would not be surprised if the EZPZ Trading website, which currently states a 1.5B total short position (1.44B synthetic), turns out to be substantially correct, or even too conservative.
https://ezpztrading.com/market-data/stocks/short-interest/?symbol=NWBO
Each person can plug in their own assumptions, but the “over-voting” is a massive statistical anomaly that we as Retail NWBO investors cannot ignore.
Side notes:
1. Is 28% too conservative? The Broadridge report say small/microcap companies have the lowest participation rates. So a more realistic OTC average rate could imply an even larger total short position.
2. “Trimming services”: Even if 3B or 4B shares were “eligible” to vote, NWBO would never see it. Brokerages use 'Trimming Services' to remove over-voting before results are certified.
Bullish
Sharing thoughts and opinions. To participate in group due diligence. Motto: Do not be a gullible FUDdable investor.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
